ALS does cause inflammation, both in the brain and spinal cord and throughout the body. This inflammation is now considered one of the defining features of the disease, not just a side effect. In people with ALS, immune cells in the central nervous system become chronically activated, inflammatory molecules rise in the blood and spinal fluid, and the protective barrier between the bloodstream and brain begins to break down. Understanding this inflammatory process matters because it appears to directly influence how fast the disease progresses.
How Inflammation Develops in ALS
The central nervous system has its own resident immune cells called microglia, which normally patrol for damage and help maintain healthy tissue. In ALS, these cells become overactivated. Rather than simply cleaning up damaged motor neurons, they begin releasing inflammatory signals that recruit other immune cells, including a type of brain cell called astrocytes and immune cells from the bloodstream like natural killer cells and certain white blood cells. These cells communicate with each other in ways that reshape the local environment around motor neurons, pushing it toward a persistently inflamed state.
This crosstalk between microglia, astrocytes, and infiltrating immune cells is now considered a central feature of ALS progression. Research has shifted from viewing ALS as purely a disease of motor neurons to recognizing the pivotal role these non-neuronal cells play. The inflammatory environment they create accelerates damage to motor neurons that are already under stress.
Inflammation Changes as the Disease Progresses
One of the most important things about ALS-related inflammation is that it isn’t static. Early in the disease, the immune response actually appears to be protective. During periods of slow progression, the immune system secretes anti-inflammatory factors that help rescue and repair damaged tissue. But as motor neuron injury accumulates, a shift occurs: the beneficial immune response gives way to a strongly pro-inflammatory, neurotoxic state that accelerates decline.
This dual nature makes inflammation in ALS unusually complex. The same immune system that initially tries to limit damage eventually becomes part of the problem. Whether neuroinflammation is a primary driver of motor neuron death or a secondary reaction to cell damage remains an open question. Both are likely true at different stages. What’s clear is that once the inflammatory shift happens, it feeds a cycle where inflammation causes more neuron damage, which triggers more inflammation.
Inflammation Beyond the Brain
ALS-related inflammation isn’t confined to the central nervous system. It shows up in the blood too. A study of 394 ALS patients published in JAMA Neurology found that higher blood levels of C-reactive protein (CRP), a common marker of systemic inflammation, correlated with worse disability scores and shorter survival. Patients with elevated CRP progressed more rapidly than those with lower levels. This suggests the inflammatory process in ALS is body-wide, not just localized to the brain and spinal cord.
Researchers have also measured elevated levels of several signaling molecules in the blood and spinal fluid of ALS patients. Some of these are pro-inflammatory, while others are anti-inflammatory molecules the body produces in an apparent attempt to fight back. Higher levels of certain protective signals in the spinal fluid, like IL-10 and IL-9, predict longer survival and slower disease progression. This pattern reinforces the idea that the balance between inflammatory and anti-inflammatory responses helps determine how quickly ALS advances in any given person.
The Blood-Brain Barrier Breaks Down
In a healthy brain, a tightly sealed barrier between the bloodstream and brain tissue prevents immune cells and toxic substances from entering. In ALS, this barrier deteriorates. The cells lining brain blood vessels lose their tight connections, and the structural scaffolding that holds the barrier together gets degraded by enzymes called matrix metalloproteinases.
Three inflammatory mechanisms drive this breakdown. First, a protein called TDP-43, which misfolds and accumulates in most ALS cases, triggers brain cells to release inflammatory molecules including IL-6 and TNF-alpha. These signals recruit peripheral immune cells across the weakened barrier. Second, the enzymes that degrade the barrier’s structural foundation become overactive, creating physical gaps. Third, persistent systemic inflammation remodels the barrier itself by altering its receptors and increasing the flow of immune cells into brain tissue. Once inside, these infiltrating cells release more inflammatory signals, compounding the damage.
Imaging Inflammation in Living Patients
Specialized PET brain scans can now visualize inflammation in living ALS patients. These scans use radioactive tracers that bind to a protein found on activated immune cells in the brain. Studies using these tracers consistently show increased uptake in the motor cortex, the brain region controlling voluntary movement, as well as in the corticospinal tract, frontal lobe, thalamus, and brainstem of ALS patients compared to healthy controls. Other tracers target an enzyme found on activated astrocytes and show similar patterns of increased activity in the pons and white matter.
This imaging evidence confirms that neuroinflammation is widespread in ALS, extending well beyond the areas of obvious motor neuron loss. It also opens the door to tracking inflammation over time, which could help researchers understand whether anti-inflammatory treatments are reaching their target.
The Gut Connection
Emerging evidence links ALS inflammation to changes in the gut microbiome. People with ALS tend to lose beneficial gut bacteria, including species like Akkermansia muciniphila, Bifidobacterium, and Lactobacillus. These bacteria normally produce compounds that protect the nervous system: short-chain fatty acids like butyrate, which help keep brain immune cells in a calm, protective state, and nicotinamide, a building block for cellular energy production. When these bacteria decline, gut barrier integrity weakens, allowing inflammatory bacterial products to leak into the bloodstream and drive systemic inflammation that can reach the brain.
Targeting Inflammation With Treatment
Because inflammation plays such a clear role in ALS progression, several clinical trials have tested whether dampening it can slow the disease. Results so far have been mixed but instructive. A drug called NP001, which regulates immune cell activation, did not show significant benefit across all ALS patients in its Phase 2B trial. But when researchers looked specifically at patients who had elevated CRP levels at the start of the trial (indicating active systemic inflammation), the results were more promising. In a subset of patients aged 40 to 65 with CRP above a certain threshold, NP001 slowed functional decline by 36% and reduced lung capacity loss by 51% compared to placebo. Among those with the highest inflammation levels (CRP above 3 mg/L), 46% of treated patients showed no disease progression at all, compared to just 4.5% on placebo.
These findings suggest that anti-inflammatory treatments may work best in patients whose disease is most heavily driven by inflammation. This fits with the broader picture: ALS likely has multiple subtypes, and inflammation plays a bigger role in some patients than others. CRP levels in the blood could eventually help identify which patients are most likely to benefit from inflammation-targeted therapies.